SARMs Recomp & Endurance Cycle: Ostarine + Cardarine with Enclomiphene PCT

Clinical Overview & Pharmacological Synergy

The Driada Medical Recomp & Endurance Stack unites two distinct non-steroidal performance modulators to optimize body composition while preserving endocrine balance. MK-2866 (Ostarine) functions as a tissue-selective androgen receptor agonist, stimulating anabolic signalling pathways in skeletal muscle and bone tissue without causing androgenic virilization or prostate hyperplasia. When searching for proven protocols, athletes frequently evaluate premium SARMs to achieve high tissue selectivity, accelerating nitrogen retention and myofibrillar protein synthesis during targeted caloric deficits. Ostarine ensures that lean muscle mass is preserved while the body metabolises adipose stores for substrate demands.

Synergistically integrated into this bundle is Allaes Cardarine (GW-501516), a selective PPARδ receptor agonist that shifts cellular bioenergetics toward fatty acid oxidation and ramps up mitochondrial density. This prevents glucose depletion, substantially elevating aerobic capacity, VO2 max, and muscular endurance during intense conditioning blocks. As an alternative to hepatotoxic oral-steroid cycles, this combination drives vascularity and lipid metabolism without elevating liver enzymes or shutting down internal hormones, establishing an elite environment for rapid body recomposition.

Bundle Components & Packaging Specifications

• 2 × MK-2866 (Ostarine) | 10mg/tab/50tabs
• 1 × Allaes Cardarine (GW 501516) 10 mg | 10 mg / 60 capsules
• 1 × Enclomilad 12.5 mg (Enclomiphene citrate) - Driada | 50tabs | 12,5 mg/tab

8-Week Administration & Dosage Protocol

Administration Schedule, Half-Life Dynamics & PCT

Clinical administration follows a strictly calibrated 8-week cycle duration. MK-2866 (Ostarine) possesses a 24-hour elimination half-life, requiring 20 mg (two 10 mg tablets) ingested once daily with morning meals to maintain steady androgenic receptor saturation. Cardarine exhibits a 16 to 24-hour biological half-life and should be taken at 10 to 20 mg daily, ideally 45 to 60 minutes prior to cardiovascular or resistance training. For athletes structuring advanced steroid cycles, timing oral compounds around metabolic workouts enhances glycogen sparing, systemic fatty acid mobilisation, and sustained endurance without causing sudden hormonal surges or gastric distress.

Endocrine restoration is safeguarded through targeted post cycle therapy (PCT) using Enclomilad (Enclomiphene citrate). Unlike standard mixed-isomer SERMs, pure enclomiphene selectively blocks estrogenic feedback mechanisms at the hypothalamus and pituitary glands without causing adverse ocular or thrombotic side effects. Commencing directly in Week 9 at 12.5 mg daily for 3 to 4 weeks, Enclomilad rapidly elevates luteinising hormone (LH) and follicle-stimulating hormone (FSH) secretion, swiftly restoring endogenous testosterone production and completely locking in newly accrued lean muscle tissue.

Key Performance & Physiological Advantages

• Targeted Lean Tissue Preservation: MK-2866 stimulates selective myocellular androgen receptors, completely halting catabolic tissue breakdown during aggressive caloric deficits.
• Accelerated Fatty Acid Oxidation: Cardarine upregulates PPAR-delta gene expression, shifting metabolic fuel dependence directly to stubborn lipids while boosting mitochondrial density.
• Vastly Enhanced Aerobic Stamina: Dramatically delays neuromuscular fatigue, extending time-to-exhaustion and accelerating inter-set cardiovascular recovery across demanding training splits.
• Zero-Estrogen Rebound PCT: Enclomilad provides targeted central hypothalamic stimulation, reinstating native testosterone production rapidly post-cycle without negative progestogenic or estrogenic rebound.